First-in-human Study to Evaluate the Safety and Immunogenicity of Three Dose Levels of the OVX033 Coronavirus Vaccine Candidate in Healthy Volunteers

Phase 1 Completed 48 enrolled Osivax CIC 1417 Cochin Pasteur Hôpital Cochin Paris France · collab

RandomizedSequentialDouble-blindPrevention

Summary

This first-in-human clinical trial is designed to evaluate the safety and immunogenicity of one administration of OVX033 coronavirus vaccine at different dose levels (100µg, 250µg and 500µg)

Timeline

Start: 2024-01-08
Primary completion: 2024-07-08
Completion: 2024-11-29

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	OVX033	Vaccine	100 ug	Intramuscular
Subject	OVX033	Vaccine	250 ug	Intramuscular
Subject	OVX033	Vaccine	500 ug	Intramuscular

First-in-human Study to Evaluate the Safety and Immunogenicity of Three Dose Levels of the OVX033 Coronavirus Vaccine Candidate in Healthy Volunteers

Summary

Timeline

Drugs

Indications